In Depth 18 Sep 2024
Two targets, one solution: The rise of bispecific antibodies
Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape looks like.
Monoclonal antibodies
- Latest Posts
ADCs that deliver: The secret lies in rigorous characterization
Explore the challenges of ADC characterization, key techniques, and the benefits of partnering with a CDMO for effective development.
The crucial role of GS-CHO innovation in biopharmaceutical progress
Learn how GS-CHO systems are advancing to improve yields and quality in biomanufacturing, meeting the rising need for effective therapeutic proteins.
Best in Biotech 2 May 2024
Eight monoclonal antibody biotechs making strides in the clinic
In this article, we take a look at eight biotechs advancing their monoclonal antibodies through the clinic that have made the news in recent times.
Biologics testing: The right time to move to new standards?
Discover the challenges facing biologics testing and how modern methods like NGS are revolutionizing quality control, ensuring safety and efficacy.
Large molecule manufacturing: addressing challenges with strategies for success
Discover the landscape of large molecule manufacturing, exploring challenges, latest innovations, and winning strategies for success.
ADVERTISEMENT
ADVERTISEMENT
Best in Biotech 29 Feb 2024
6 biotech companies making a difference in pediatric care
Take a closer look at six pediatric companies taking innovative approaches to tackle illnesses affecting children.
News and Trends 20 Jul 2023
Mage Biologics created to develop oral antibody therapy for ulcerative colitis
TVM Capital Life Science and specialty pharma company Tillotts Pharma are to jointly invest up to $28 million in a newly formed U.S.-based biotechnology company, Mage Biologics Inc. TVM will invest with its TVM Life Science Innovation II SCSp (TVM LSI II) fund and will provide strategic advice to Mage Bio. Mage Bio is the […]
News and Trends 17 Jul 2023
Lilly boosts obesity portfolio with Versanis Bio acquisition
Eli Lilly and Company is set to acquire Versanis Bio in a deal that could be worth close to $2 billion. Versanis Bio is a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II […]
News and Trends 27 Jun 2023
UCB myasthenia gravis drug given FDA approval
UCB has announced RYSTIGGO (rozanolixizumab-noli) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. Rozanolixizumab-noli injection for subcutaneous infusion is a humanized IgG4 monoclonal antibody that binds to the neonatal […]
News and Trends 1 Jun 2023
Sanofi drug reduces disease activity in relapsing MS
New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a phase 2 trial of patients with relapsing multiple sclerosis (MS). Following 12 weeks of therapy, […]
News and Trends 14 Apr 2023
TORL BioTherapeutics launches with $158M to target cancer
TORL BioTherapeutics LLC, a biopharmaceutical company focused on developing new biologics for cancer treatment, has announced its public launch and the closing of a $158 million Series B financing. TORL’s pipeline of antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) were discovered in the laboratory of scientific co-founder Dennis Slamon, professor of medicine, and chief of […]
ADVERTISEMENT